Nebenwirkungen · Topotecan Hospira
Topotecan Hospira 4 mg/4 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 7
HOS-122965 · Präparat HOS-095615
Thrombocytopenia Severe (platelets <25 x 109/l) in 25% of patients (8% of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25% of patients (15% of courses). Median time to onset of severe thrombocytopenia, was day 15 and the median duration was five days. Platelet transfusions were given in 4% of courses. Reports of significant sequelae associated with thrombocytopenia including fatalities due to tumour bleeds, have been infrequent.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-31T11:50:00Z · SHA-256 51b338badc1d33edf5bf2700d056d46275447e6a3f83ae2173852608cc281250 · Passage ef7d373a6c33c6a84df415cd3e430e6f2cba22dca58bd59cfaaf55c9050bf5d8 · Zeichen 5337–5788 im Abschnitt